David Polinsky
Known title: Former Chief Financial OfficerCIK: 0001726896
Associated companies
Transaction History
| RFL | ▼ Sell | Tax Withholding | 2,386 | $6K | 6/21/2026 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,318 | $3K | 3/21/2026 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 4,865 | $6K | 1/13/2026 | View on chart |
| RFL | ▲ Buy | Grant | 50,000 | $62K | 1/13/2026 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 1,961 | $3K | 12/21/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 4,180 | $6K | 10/25/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 1,284 | $2K | 9/23/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 1,970 | $3K | 9/21/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,347 | $4K | 6/21/2025 | View on chart |
| RFL | ▼ Sell | Other | 76,882 | $98K | 5/29/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,378 | $5K | 3/21/2025 | View on chart |
| RFL | ▲ Buy | Grant | 50,000 | $98K | 1/13/2025 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,002 | $4K | 12/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 3,331 | $6K | 10/25/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 1,431 | $2K | 9/23/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,384 | $4K | 9/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,296 | $3K | 6/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,300 | $4K | 3/21/2024 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 8,577 | $16K | 12/21/2023 | View on chart |
| RFL | ▲ Buy | Grant | 40,000 | $61K | 10/25/2023 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 2,541 | $5K | 9/23/2023 | View on chart |
| RFL | ▼ Sell | Tax Withholding | 571 | $20K | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Rafael Holdings stock drops after Phase 3 trial misses goal
Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.
Rafael Holdings stock drops after Phase 3 trial misses goal. Rafael Holdings shares fell sharply after the company reported that its Phase 3 TransportNPC study for Trappsol Cyclo did not achieve statistical significance in treating Niemann-Pick Disease Type C. The trial involved 94 patients, and the lack of efficacy results led to a significant decline in the stock price. This outcome highlights the risks associated with late-stage clinical trials for rare disease treatments.